Under clinical study, patients with COVID-19 orally took a genetically modified probiotic, Lactococcus lactis, which secreted the target ~34 kDa protein, consisting of seven repeats of the mature human LL-37 alternating with enterokinase. The gene discussed is CAMP; the disease is COVID-19.